The Danaher acquisition of Masimo was officially finalized on June 10, 2026, marking a significant clinical advancement for global healthcare technology pipelines. Danaher Corporation (NYSE: DHR), a prominent global science and technology innovator headquartered in Washington, announced the successful completion of the transaction to acquire Masimo Corporation. This acquisition infuses Masimo’s specialized pulse oximetry systems and advanced patient monitoring solutions directly into Danaher’s expanding medical infrastructure.
Following the close of the transaction, Masimo operates as a wholly-owned subsidiary of Danaher, causing Masimo common stock to officially cease trading on the Nasdaq Stock Market. To preserve its deep clinical market presence, the acquired business will continue to navigate the medical industry under its traditional, trusted Masimo brand. Organizationally, it will be positioned as a stand-alone operating company within Danaher’s Diagnostics segment, deploying its proprietary sensor technology alongside established laboratory brands.
Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo’s growth and global reach.
Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher
Corporate Guidance and Financial Integration Plans After the Danaher Acquisition of Masimo
Addressing the immediate financial trajectory, Danaher announced that there is no change to its previously communicated second-quarter and full-year 2026 guidance ranges, which currently exclude the financial contributions of the newly acquired company. Executive leadership does not project a material financial contribution from Masimo during the second quarter of 2026. However, Danaher intends to formally update its full-year 2026 guidance framework during its upcoming second-quarter earnings release to explicitly incorporate Masimo’s projected baseline contributions.
The definitive transaction materials specifying terms and consideration payable to former stockholders have been filed with the U.S. Securities and Exchange Commission. Corporate documentation outlines several essential risk parameters that could influence the execution of the Danaher acquisition of Masimo, such as debt obligations incurred to finance the deal, international tariffs, and uncertainties regarding artificial intelligence deployment. Financial analysts who track diagnostic sector shifts can review our internal reporting on Danaher segment performance to evaluate how these variables fit into broader operational timelines.
As a global life sciences innovator, Danaher anchors its operational expansion on approximately 60,000 associates worldwide who are committed to accelerating the power of science to improve human health. This massive footprint relies heavily on the foundational Danaher Business System (DBS), a set of core principles designed to drive continuous improvement, reduce clinical development risks, and accelerate diagnostic accuracy. Deployed strategically, this methodology will support the scaling of Masimo’s AI-enabled non-invasive software tools to a much wider international hospital base.
Transaction and Entity Profiles
| Metric Classification | Parameter Details | Source Reference Verification |
| Acquiring Corporate Entity | Danaher Corporation (NYSE: DHR) | Official press release text |
| Acquisition Target Entity | Masimo Corporation (Ex-NASDAQ) | Official press release text |
| Transaction Closing Date | June 10, 2026 | Effective date of corporate action |
| Primary Product Category | Pulse oximetry & patient monitoring solutions | Target core business focus |
| Core Operational Environments | Acute care treatment settings | Targeted clinical workflows |
| Post-Acquisition Status | Wholly-owned subsidiary of Danaher | Final operational relationship |
| Stock Market Action | Ceased trading on the Nasdaq Stock Market | Securities delisting consequence |
Segment Placement and Governance
| Parameter Category | Integration Strategy | Structural Specification |
| Parent Corporate Segment | Danaher Diagnostics Segment | Operational segment allocation |
| Subsidiary Governance Model | Stand-alone operating company | Management autonomy framework |
| Brand Management Policy | Retains the original Masimo brand name | Market-facing identity retention |
| Segment Executive Leadership | Julie Sawyer Montgomery | Executive Vice President of Diagnostics |
| Parent Operational Framework | Danaher Business System (DBS) | Operational excellence engine |
| Global Associate Footprint | Approximately 60,000 associates worldwide | Parent company workforce capacity |
Financial Guidance and Risk Vector Mapping
| Guidance Parameter | Current Fiscal Status | Risk Factor Matrix Components |
| Q2 2026 Corporate Guidance | Unchanged (Excludes Masimo numbers) | No material contribution expected in Q2 |
| Full-Year 2026 Guidance Update | Scheduled for second-quarter earnings release | Dependent on integration and global economics |
| Regulatory Filing Location | U.S. Securities and Exchange Commission | Definitive transaction materials repository |
| Transaction Financing Impact | Debt obligations incurred for financing | Operational liquidity consideration |
| Technological Risk Variable | Deployment and use of artificial intelligence | Software innovation and compliance uncertainty |
| Global Operational Risk Vectors | Tariffs, trade policies, and geopolitical events | Includes specific global health or regional conflicts |
